Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 935-783-6 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicity to reproduction
Administrative data
- Endpoint:
- two-generation reproductive toxicity
- Remarks:
- based on test type (migrated information)
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- GLP compliant OECD guideline 416 study, tested with the source substance CAS 59-50-7. According to the ECHA guidance document “Practical guide 6: How to report read-across and categories (March 2010)”, the reliability was changed from RL1 to RL2 to reflect the fact that this study was conducted on a read-across substance.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 006
- Report date:
- 2006
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 416 (Two-Generation Reproduction Toxicity Study)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.3800 (Reproduction and Fertility Effects)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Chlorocresol
- EC Number:
- 200-431-6
- EC Name:
- Chlorocresol
- Cas Number:
- 59-50-7
- Molecular formula:
- C7H7ClO
- IUPAC Name:
- 4-chloro-3-methylphenol
- Details on test material:
- - Name of test material (as cited in study report): 4-Chloro-3-methylphenol
- Physical state: Pastilles
- Analytical purity: 100%
- Lot/batch No.: CHT0126 and CHA0152
- Stability under test conditions: until 2006-10-07 and 2007-12-12, respectively.
Stability and homogeneity in diet approved for up to 15 days in 15 kg mixtures
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Wistar Crl: (WI) WU BR
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River GmbH, Sulzfeld, Germany
- Age at study initiation: (P): 5-6 weeks, (F1): 4 weeks
- Weight at study initiation: (P) Males:113-149 g; Females: 95-122 g; (F1) Males: 61-120 g; Females: 62-110 g
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Details on mating procedure:
- The first F0 or F1 male was caged overnight with the first F0 or F1 female from the same test group (and so on) for maximum 12 times.
Mating was performed up to 3 weeks or until spermatozoa were observed in vaginal smears taken the next morning. On day 4 of lactation litters were culled to 8 pups/litter. F1 offspring were nursed up to an age of four weeks. Some of them were selected for further treatment (12 weeks) and for breeding an F2a generation. A second mating of F1 animals was performed giving rise to F2b litters to clarify relatively low viability indices at 0 and 3000 ppm. - Analytical verification of doses or concentrations:
- yes
- Duration of treatment / exposure:
- F0 animals: from beginning of the study until sacrifice. F0 animals were treated beginning 10 weeks before mating.
F1 animals: from weaning until sacrifice
F2 animals: sacrifice after weaning
Parental F0 animals received the test substance for a period of about 10 weeks before mating and were then allowed to mate over a period of up to three weeks. F1 offspring were nursed up to an age of four weeks. Some of them were selected for further treatment (12 weeks) and for breeding a F2 generation. - Frequency of treatment:
- daily (free access to food containing the test stubstance)
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
750, 3000, 12000 ppm
Basis:
nominal in diet
- Remarks:
- Doses / Concentrations:
63.8, 247.8, 1043.0 mg/kg bw/d (F0 males pre-mating period)
Basis:
other: mean dose as calculated from the reported body weight and standard food intake values
- Remarks:
- Doses / Concentrations:
74.5, 288.4, 1204.9 mg/kg bw/d (F1 males pre-mating period)
Basis:
other: mean dose as calculated from the reported body weight and standard food intake values
- Remarks:
- Doses / Concentrations:
80.1, 298.2, 1189.7 mg/kg bw/d (F0 females pre-mating period)
Basis:
other: mean dose as calculated from the reported body weight and standard food intake values
- Remarks:
- Doses / Concentrations:
90.4, 364.5, 1263.4 mg/kg bw/d (F1 females pre-mating period)
Basis:
other: mean dose as calculated from the reported body weight and standard food intake values
- No. of animals per sex per dose:
- 25 per sex per dose (P and F1)
- Control animals:
- yes, concurrent no treatment
Examinations
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS: Yes, once daily for clinical signs and twice daily for mortality and morbidity.
BODY WEIGHT: Yes, Body weights were recorded directly prior to the first administration and thereafter weekly up to necropsy (males and females not pregnant) and during the pregnancy and lactation periods as follows:
- During pregnancy on Day p.c. 0, 7, 14 and 20.
- During lactation on Day p.p .0, 4, 7, 14, 21 and 28.
- On the day of scheduled necropsy.
FOOD CONSUMPTION: Yes, Males: Weekly from week 1 up to necropsy (except during mating period).
-Females: Weekly from week 1 up to mating.
During pregnancy Day p.c. 0-7; 7-14; 14-20.
During lactation Day p.p. 0-4; 4-7. - Oestrous cyclicity (parental animals):
- Oestrus cycle length determination was done by evaluation of vaginal smears received daily over 19 consecutive days prior to the mating period. The smears were examined microscopically for large set-rated cells indicating that oestrus had occurred. This data was used to determine the oestrus cycle length and whether females were cycling properly.
- Sperm parameters (parental animals):
- Spermatological investigations were performed in all surviving F0 and F1 males of the 0 and 12000 ppm group on the day of necropsy.
The following spermatozoa parameters were assessed:
motility and viability, morphology, epididymal spermatozoa count, count of homogenisation-resistant spermatid heads in the testis - Litter observations:
- STANDARDISATION OF LITTERS
- Performed on day 4 postpartum: yes, litters were culled to 8 pups/litter
PARAMETERS EXAMINED
The following parameters were examined in offspring:
Number of live and dead pups, pup weight, external alterations, ano-genital distance (in F2a pups), sex of each pup, developmental milestones (balano-preputial separation, vaginal opening) - Postmortem examinations (parental animals):
- GROSS NECROPSY
Necropsies were done on all rats. Implantation sites in F0 and F1 females were recorded.
ORGAN WEIGHTS: Selected organs were weighed in adult rats and weanlings: Adrenals, brain, epididymides, kidneys, liver, ovaries and oviducts, pituitary, prostate, seminal vesicle and coagulating glands, spleen, testes, thyroid/parathyroids, uterus w/ cervix
HISTOPATHOLOGY
The following organs and tissues were examined at least in the control and high-dose group (including ovarian follicle staging (only F1)). This included also all F0/F1 rats which died intercurrently and those which were sacrificed moribund.
Abnormalities, adrenals, brain, epididymides, oesophagus, kidneys, larynx, liver, ovaries and oviducts, pituitary, prostate, seminal vesicle and coagulating glands, skin in mammary region, testes, thyroid/parathyroids, trachea, uterus w/ cervix, vagina, head w/ scull cap - Postmortem examinations (offspring):
- GROSS NECROPSY
Apparently abnormal tissues, if any, were fixed in all pups/weanlings. In F1, F2a and F2b weanlings, brain, spleen, thymus, uterus and kidneys of one male and one female out of the first necropsied 5 litters per group were preserved in formalin.
ORGAN WEIGHT
The brain, spleen, thymus and uterus of one male and one female per F2a and F2b litter were trimmed and weighed as soon as possible after dissection. The ratio of organ weights to body weights was calculated. Therefore, all these weanlings were weighed at day of necropsy.
Results and discussion
Results: P0 (first parental generation)
General toxicity (P0)
- Clinical signs:
- no effects observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- starting at 3000 ppm in F1 animals
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- starting at 3000 ppm in F1 animals
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- starting at 3000 ppm in F1 animals
- Other effects:
- effects observed, treatment-related
- Description (incidence and severity):
- Test substance intake: At 12000 ppm F1 females ingested less than control animals.
Reproductive function / performance (P0)
- Reproductive function: oestrous cycle:
- effects observed, treatment-related
- Description (incidence and severity):
- at 12000 ppm in F0 and F1 animals
- Reproductive function: sperm measures:
- no effects observed
- Reproductive performance:
- no effects observed
Details on results (P0)
F0 animals: No effects were seen in F0 animals and F1 pups of control, low and mid dose.
At the high dose, findings in F0 males comprised of:
Reduced body weight during pre-mating; reduced glycogen stores and altered fat deposition in the liver and hyaline casts and tubulus dilation in the kidneys.
Findings in F0 females at the high dose level comprised of:
Reduced body weight during pre-mating, gestation and lactation; increased relative liver weights, reduced glycogen stores, hypertrophy and altered fat deposition in the liver; increased tubulus epithelium inclusion, tubulus dilation and basophilic tubules in the kidney; smaller ovaries, ovary athrophy/changed cycle and epithelium athrophy of the vagina.
F1 animals: No effects were seen in animals of control and low dose.
Findings in F1 males comprised of:
At the mid dose, reduced absolute and relative liver weights.
At the high dose, reduced body weight during pre-mating, reduced absolute and relative liver weights, reduced glycogen stores and altered fat deposition in the liver, increased weights of the seminal vesicles and necrosis, simple tubulus dilation and hyaline casts in the kidney.
The increased weights of the seminal vesicles noted in F1 males were not considered to be treatment related as examinations on sperms revealed no effect. The liver changes (reduced hepatocellular glycogen storage, reduced periportal fat storage, adaptive periportal hypertrophy) might reflect secondary catabolic effects in course of a significant body weight loss in high dose animals and are associated with decreased liver weights in 3000 and 12,000 ppm F1 males
Findings in F1 females comprised of:
At the mid dose, reduced body weight during lactation, hypertrophy and altered fat deposition of the liver and simple tubulus dilation and tubulus dilation of the kidney.
At the high dose, reduced body weight during pre-mating, gestation and lactation; dilated stomach/caecum and emaciation; reduced glycogen stores and altered fat deposition of the liver; necrosis, tubulus dilation and increased relative weights of the kidney, the adrenals and the spleen; reduced weight of ovaries, ovary athrophy/changed cycle (increased metoestrus, decreased dioestrus) reduced growing follicles and reduced corpora lutea
The statistically significantly increased relative weights of the adrenals and spleen in F1 females were not considered to be adverse as histological correlates are missing. The ovarian atrophy, increased metoestrus, decreased dioestrus and atrophy of the vaginal epithelium as well as the decreased number of growing follicles and corpora lutea in F1 rats are considered to be possibly secondary due to weight loss and are correlated with reduced ovary weights and/or smaller ovaries.
Effect levels (P0)
open allclose all
- Dose descriptor:
- LOAEL
- Effect level:
- 1 043 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: Basis for effect level: body weight; some organ weights Remark: 1043 mg/kg bw corresponds to 12000 ppm (mean dose value as calculated from the body weight and food intake values)
- Dose descriptor:
- LOAEL
- Effect level:
- 1 190 mg/kg bw/day
- Based on:
- test mat.
- Remarks:
- (mean dose value as calculated from the reported body weight and food intake values)
- Sex:
- female
- Basis for effect level:
- other: Basis for effect level: body weight; some organ weights; smaller ovaries Remark 1190mg/kg bw/day corresponds to 12000 ppm (mean dose value as calculated from the body weight and food intake values)
- Dose descriptor:
- NOAEL
- Effect level:
- 248 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: Basis for effect level: No effects were seen at this dose level. Remark: 248 mg/kg bw/day corresponds to 3000ppm (mean dose value as calculated from the body weight and food intake values)
- Dose descriptor:
- NOAEL
- Effect level:
- 288 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: Basis for effect level: No effects were seen at this dose level. Remark: 288 mg/kg bw/day corresponds to 3000 ppm (mean dose value as calculated from the body weight and food intake values)
Results: F1 generation
General toxicity (F1)
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- at 12000 ppm in F2a pups
- Mortality / viability:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- starting at 3000 ppm in F2b pups
- Sexual maturation:
- not specified
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- at 12000 ppm in F1 and F2a/F2b pups
- Gross pathological findings:
- no effects observed
- Histopathological findings:
- not specified
Details on results (F1)
F1 pups: No effects were seen in F0 animals and F1 pups of control, low and mid dose
F1 pups: At the high dose reduced pup weights, reduced litter weights, reduced absolute and/or relative spleen and thymus weights were recorded.
The occurrence of developmental milestones (balano-preputial separation and vaginal opening) was delayed in F1 rats of the high dose group.
F2a and F2b pups: No effects were seen in animals of control and low dose.
Findings of the F2a pups comprised of:
At the high dose reduced pup weights, reduced absolute and/or relative spleen and thymus weights and clinical signs of toxicity. No effects were seen in pups of the lower dose ranges. The amount of autolytic pups for F2a pups was at the highest dose group higher than in the other groups.
Findings of the F2b pups comprised of:
At the high dose reduced pup weights, reduced litter weights, reduced absolute and /or relative spleen and thymus weights and clinical signs of toxicity. No effects were seen in pups of the lower dose ranges. At the mid dose reduced pup weights were noticed.
Effect levels (F1)
open allclose all
- Dose descriptor:
- LOAEL
- Remarks:
- pups (LOAEL for pup effect is based on the lowest maternal dose during gestation/lactation )
- Generation:
- F1
- Effect level:
- 862 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Basis for effect level: pup/litter weight; spleen and thymus weights Remark: 862 mg/kg bw/day corresponds to 12000 ppm (mean dose value as calculated from the body weight and food intake values)
- Dose descriptor:
- LOAEL
- Generation:
- F1
- Effect level:
- 248 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: Basis for effect level: some organ weights Remark: 248mg/kg bw/day corresponds to 3000 ppm (mean dose value as calculated from the body weight and food intake values)
- Dose descriptor:
- LOAEL
- Generation:
- F1
- Effect level:
- 298 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: Basis for effect level: body weight; gross pathology and histopathology of liver and kidney Remark: 298 mg/kg bw/day corresponds to 3000 ppm (mean dose value as calculated from the body weight and food intake values)
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- 75 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: Basis for effect level: No effects were seen at this dose level. Remark: 75 mg/kg bw/day corresponds to 750 ppm (mean dose value as calculated from the body weight and food intake values)
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- 90 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: Basis for effect level: No effects were seen at this dose level. Remark: 90 mg/kg bw/day corresponds to 750 ppm (mean dose value as calculated from the body weight and food intake values)
- Dose descriptor:
- NOAEL
- Remarks:
- pups (NOAEL for pup effect is based on the lowest maternal dose during gestation/lactation)
- Generation:
- F1
- Effect level:
- 54 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Basis for effect level: No effect was seen at this dose level. Remark: 54 mg/kg bw/day corresponds to 750 ppm (mean dose value as calculated from the body weight and food intake values)
Results: F2 generation
Effect levels (F2)
open allclose all
- Dose descriptor:
- LOAEL
- Remarks:
- pups (LOAEL for pup effect is based on the lowest maternal dose during gestation/lactation)
- Generation:
- F2a
- Effect level:
- 982 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Basis for effect level:body weight; spleen and thymus weight Remark: 982 mg/kg bw/day corresponds to 12000 ppm (mean dose value as calculated from the body weight and food intake values)
- Dose descriptor:
- LOAEL
- Remarks:
- pups (LOAEL for pup effect is based on the lowest maternal dose during gestation/lactation)
- Generation:
- F2b
- Effect level:
- 195 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Basis for effect level: body weight Remark 195 mg/kg bw/day corresponds to 3000 ppm (mean dose value as calculated from the body weight and food intake values)
- Dose descriptor:
- NOAEL
- Remarks:
- pups (NOAEL for pup effect is based on the lowest maternal dose during gestation/lactation)
- Generation:
- F2a
- Effect level:
- 235 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Basis for effect level: No effects were seen at this dose level. Remark: 235 mg/kg bw/day corresponds to 3000 ppm (mean dose value as calculated from the body weight and food intake values)
- Dose descriptor:
- NOAEL
- Remarks:
- pups (NOAEL for pup effect is based on the lowest maternal dose during gestation/lactation)
- Generation:
- F2b
- Effect level:
- 47 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Basis for effect level: No effect was seen at this dose level. Remark: 47 mg/kg bw/day corresponds to 750 ppm (mean dose value as calculated from the body weight and food intake values)
Overall reproductive toxicity
- Reproductive effects observed:
- not specified
Any other information on results incl. tables
Table 1: Summary of effects seen within the two generation study
|
F0 rearing F1 |
F1 rearing F2a |
F1 rearing F2b |
||||||
Dose [ppm] |
750 |
3000 |
12000 |
750 |
3000 |
12000 |
750 |
3000 |
12000 |
Parental animals |
|
|
|
||||||
Body weight: Premating |
|
|
↓ |
|
|
↓ |
- |
- |
- |
Body weight: Gestation |
|
|
↓ |
|
|
↓ |
|
|
↓ |
Body weight: Lactation |
|
|
↓ |
|
↓ |
↓ |
|
↓ |
↓ |
Food intake: Premating |
|
|
|
|
|
↓ F |
- |
- |
- |
Developmental milestones |
- |
- |
- |
|
|
→ |
- |
- |
- |
Necropsy |
|
|
|
||||||
Liver weights (absolute and relative) |
|
|
|
|
|
|
|
↓ M |
↓ M |
Liver weights (relative) |
|
|
↑ F |
|
|
|
|
|
↑ F |
Seminal vesicles weight (absolute and relative) |
|
|
|
|
|
|
|
|
↑ |
Ovaries weight |
|
|
↓ |
- |
- |
- |
|
|
↓ |
Ovaries diminished in size |
|
|
yes |
- |
- |
- |
|
|
|
Ovaries growing follicles |
- |
- |
- |
|
|
|
|
|
↓ |
Ovaries corpora lutea |
- |
- |
- |
|
|
|
|
|
↓ |
Stomach/cecum dilated |
|
|
|
|
|
|
|
|
yes F |
Emaciation |
|
|
|
|
|
|
|
|
yes F |
Ovary athropie/changed cycle |
|
|
yes F |
|
|
|
|
|
yes F |
Vagina epithelium athrophy |
|
|
yes F |
|
|
|
|
|
yes F |
Kidney, adrenals, spleen weight (relative) |
|
|
|
|
|
|
|
|
↑ F |
Liver hypertrophy |
|
|
yes F |
|
|
|
|
yes F |
yes F |
Liver reduced glycogen |
|
|
yes |
|
|
|
|
|
yes |
Liver fat deposition changed |
|
|
yes |
|
|
|
|
yes F |
yes |
Kidney necrosis |
|
|
|
|
|
|
|
|
yes |
Kidney simple tubulus dilation |
|
|
|
|
|
|
|
yes F |
yes |
Kidney tubulus epithel inclusion |
|
|
↑ F |
|
|
|
|
|
↑ F |
Tubulus dilation |
|
|
yes F |
|
|
|
|
yes F |
yes F |
Kidney basophilic tubules |
|
|
yes F |
|
|
|
|
|
yes M |
Hyaline casts/ tubulus dilation |
|
|
yes M |
|
|
|
|
|
↓ M |
Litter/Pup data |
|
|
|
||||||
Pup weights |
|
|
↓ |
|
|
↓ |
|
↓ |
↓ |
Litter weights |
|
|
↓ |
|
|
|
|
|
↓ |
Clinical signs |
|
|
|
|
|
yes |
|
|
|
spleen weights |
|
|
↓ |
|
|
↓ |
|
|
↓ |
Thymus weights |
|
|
↓ |
|
|
↓ |
|
|
↓ |
↓ = decrease; ↑ = increase; → = delayed - = not measured, yes = finding present F = females only, M = males only |
The parameters of the reproductive performance such as insemination, fertility, gestation and rearing indices as well as gestation length were not influenced by the treatment with the test substance up to 12000 ppm.
There was no test substance-related reduction in viability and lactation indices up to 12000 ppm.
Table 2: Test substance intake by dams during gestation and lactation
Dietary concentration [ppm] |
Generation (females) |
Mean test substance consumption |
|
day 14 to 20 p.c. |
Day 0 to 4 p.p. |
||
750 |
F0 |
54.2 ± 3.08 |
89.2 ± 32.97 |
F1 rearing litter F2a |
55.8 ± 7.55 |
83.0 ± 31.65 |
|
F1 rearing litter F2b |
46.6 ± 6.78 |
86.7 ±27.61 |
|
3000 |
F0 |
216.8 ± 14.60 |
320.7 ± 110.53 |
F1 rearing litter F2a |
235.3 ± 35.55 |
345.1 ± 125.47 |
|
F1 rearing litter F2b |
195.1 ± 24.36 |
279.7 ± 84.01 |
|
12000 |
F0 |
861.8 ± 85.46 |
1385.8 ± 431.38 |
F1 rearing litter F2a |
982.3 ± 199.80 |
1582.8 ± 525.45 |
|
F1 rearing litter F2b |
773.4 ± 100.17 |
1495.3 ± 417.4 |
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.